Results 1 to 10 of about 35,157 (142)

FGFR2 modulates the Akt/Nrf2/ARE signaling pathway to improve angiotensin II-induced hypertension-related endothelial dysfunction

Clinical and Experimental Hypertension, 2023
Background Fibroblast growth factor receptor (FGFR)2 expression was decreased in hypertension patients while its role in hypertension was not explored. This experiment aimed to investigate the expression ofFGFR2 in angiotensin II (Ang II)-induced human ...
Kun Jiao, Ping Su, Yongling Li
doaj   +2 more sources

FGFR2 overexpression and compromised survival in diffuse-type gastric cancer in a large central European cohort

PLoS ONE, 2022
The significance of fibroblast growth factor receptor 2 (FGFR2) in gastric cancer (GC) has been studied predominantly in Asian patient cohorts. Data on White patients are scarce.
Thorben Schrumpf, Hans-Michael Behrens, Jochen Haag, Sandra Krüger, Christoph Röcken   +4 more
doaj   +3 more sources

Activated FGFR2 signalling as a biomarker for selection of intrahepatic cholangiocarcinoma patients candidate to FGFR targeted therapies

Scientific Reports
FGFR inhibitors have been developed to inhibit FGFR activation and signal transduction; notwithstanding, currently the selection of intrahepatic cholangiocarcinoma (iCCA) patients for these drugs only relies on the detection of FGFR2 genetic alterations (
Giovanni Brandi, Valeria Relli, Marzia Deserti, Andrea Palloni, Valentina Indio, Annalisa Astolfi, Salvatore Serravalle, Alessandro Mattiaccio, Francesco Vasuri, Deborah Malvi, Chiara Deiana, Maria Abbondanza Pantaleo, Matteo Cescon, Alessandro Rizzo, Masaru Katoh, Simona Tavolari   +15 more
doaj   +2 more sources

Genomic complexity in advanced gastric and esophageal adenocarcinomas: a case report of rare WDR11-AS1-FGFR2 fusions [PDF]

Frontiers in Oncology
Fibroblast growth factor receptor 2 (FGFR2) alterations represent an emerging therapeutic target in gastroesophageal adenocarcinoma (GEA). Although FGFR2 amplifications and overexpression have been associated with poor prognosis and therapeutic ...
Eric Mehlhaff, Dustin A. Deming, Dustin A. Deming, Jeremy D. Kratz, Jeremy D. Kratz, Jeremy D. Kratz, Khaldun Obeidat, Lauren Welch, Nataliya Uboha, Nataliya Uboha   +9 more
doaj   +2 more sources

The Role of FGFR2 as a Novel Biomarker for Treatment of Gastric Cancer—A Literature Review [PDF]

Medicina
Background: Gastric cancer currently has the third highest mortality rate worldwide among cancer types. Despite gradual declines in mortality rates attributed to improvements in early detection and treatment, outcomes for advanced-stage disease are still
João Lages dos Santos, Rui Caetano Oliveira, João Martins Gama   +2 more
doaj   +2 more sources

Futibatinib for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma.

New England Journal of Medicine, 2023
BACKGROUND Alterations in fibroblast growth factor receptor 2 (FGFR2) have emerged as promising drug targets for intrahepatic cholangiocarcinoma, a rare cancer with a poor prognosis.
L. Goyal, F. Meric-Bernstam, A. Hollebecque, J. Valle, C. Morizane, T. Karasic, T. Abrams, J. Furuse, R. Kelley, P. Cassier, H. Klümpen, H. Chang, Li-Tzong Chen, J. Tabernero, Do-Youn Oh, A. Mahipal, M. Moehler, E. Mitchell, Y. Komatsu, Kunihiro Masuda, Daniel H Ahn, R. Epstein, A. Halim, Yao Fu, T. Salimi, V. Wacheck, Yaohua He, Mei Liu, K. Benhadji, J. Bridgewater   +29 more
semanticscholar   +1 more source

Generation of human induced pluripotent stem cell lines from patients with FGFR2-linked syndromic craniosynostosis

Disease Models & Mechanisms
Max Gijsbertsen, Irene M. J. Mathijssen, Ana F. Duarte Madancos, Johannes P. T. M. van Leeuwen, Jeroen van de Peppel   +4 more
doaj   +2 more sources

RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across FGFR2 Alterations and Resistance Mutations

Cancer Discovery, 2023
Unlike pan-FGFR inhibitors, RLY-4008 was designed to be selective for FGFR2 and induces clinical responses in FGFR2-altered solid tumors without clinically significant FGFR1-mediated hyperphosphatemia and FGFR4-mediated diarrhea.
V. Subbiah, V. Sahai, Dejan Maglic, Kamil Bruderek, B. Touré, Songping Zhao, R. Valverde, Patrick J O'Hearn, D. Moustakas, Heike Schonherr, Nastaran Gerami-Moayed, Alexander M Taylor, B. M. Hudson, Damian Houde, Debjani Pal, Lindsey Foster, H. Gunaydin, P. Ayaz, Dina A Sharon, L. Goyal, A. Schram, Suneel D. Kamath, C. Sherwin, O. Schmidt-Kittler, K. Jen, F. Ricard, B. Wolf, D. Shaw, D. Bergstrom, J. Watters, Jessica B Casaletto   +30 more
semanticscholar   +1 more source

Landscape of Clinical Resistance Mechanisms to FGFR Inhibitors in FGFR2-Altered Cholangiocarcinoma

Clinical Cancer Research, 2023
Purpose: FGFR inhibitors are effective in FGFR2-altered cholangiocarcinoma, leading to approval of reversible FGFR inhibitors, pemigatinib and infigratinib, and an irreversible inhibitor, futibatinib.
Qibiao Wu, H. Ellis, Giulia Siravegna, Alexa G Michel, B. Norden, F. Fece de la Cruz, E. Balasooriya, Y. Zhen, V. S. Silveira, Jianwei Che, R. Corcoran, N. Bardeesy   +11 more
semanticscholar   +1 more source

OTUB1 promotes osteoblastic bone formation through stabilizing FGFR2

Signal Transduction and Targeted Therapy, 2023
Bone homeostasis is maintained by the balance between osteoblastic bone formation and osteoclastic bone resorption. Dysregulation of this process leads to multiple diseases, including osteoporosis.
Qiong Zhu, Yesheng Fu, C. Cui, Yiyao Ding, Zhikang Deng, Chao Ning, Fan Hu, Chen Qiu, Biyue Yu, Xu Zhou, Guan Yang, Jiang Peng, Weiguo Zou, C. Liu, Lingqiang Zhang   +14 more
semanticscholar   +1 more source